A microRNA biomarker panel for the non-invasive detection of bladder cancer
Metrics: PDF 1519 views | HTML 2352 views | ?
Virginia Urquidi1, Mandy Netherton2, Evan Gomes-Giacoia2, Daniel J. Serie3, Jeanette Eckel-Passow4, Charles J. Rosser1,5, Steve Goodison1,3,6
1Nonagen Bioscience Corporation, Jacksonville, FL, USA
2Cancer Research Institute, MD Anderson Cancer Center, Orlando, FL, USA
3Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL USA
4Department of Health Sciences Research, Mayo Clinic, Rochester, MN USA
5University of Hawaii Cancer Center, Honolulu, HI USA
6Department of Urology, Mayo Clinic, Jacksonville, FL USA
Steve Goodison, email: [email protected]
Keywords: diagnostic biomarkers, bladder cancer, microRNA, multiplex, urinalysis
Received: August 15, 2016 Accepted: November 08, 2016 Published: November 16, 2016
The development of accurate, non-invasive urinary assays for bladder cancer would greatly facilitate the detection and management of a disease that has a high rate of recurrence and progression. In this study, we employed a discovery and validation strategy to identify microRNA signatures that can perform as a non-invasive bladder cancer diagnostic assay. Expression profiling of 754 human microRNAs (TaqMan low density arrays) was performed on naturally voided urine samples from a cohort of 85 subjects of known bladder disease status (27 with active BCa). A panel of 46 microRNAs significantly associated with bladder cancer were subsequently monitored in an independent cohort of 121 subjects (61 with active BCa) using quantitative real-time PCR (RT-PCR). Multivariable modeling identified a 25-target diagnostic signature that predicted the presence of BCa with an estimated sensitivity of 87% at a specificity of 100% (AUC 0.982). With additional validation, the monitoring of a urinary microRNA biomarker panel could facilitate the non-invasive evaluation of patients under investigation for BCa.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.